2024/05/24 | 15:04:16 | Announcement for the important resolutions at the 2024 Annual Shareholders’ Meeting on behalf of Medeon’s major subsidiary, Prodeon Medical Corporation | |
SEQ_NO |
1 |
Date of announcement |
2024/05/24 |
Time of announcement |
15:04:16 |
Subject |
Announcement for the important resolutions at the 2024 Annual Shareholders’ Meeting on behalf of Medeon’s major subsidiary, Prodeon Medical Corporation |
Date of events |
2024/05/24
|
To which item it meets |
paragraph 18 |
Statement |
1.Date of the shareholders’ meeting:2024/05/24 2.Important resolutions I.Profit distribution/deficit compensation: Ratification of 2023 deficit offset proposal 3.Important resolutions II.Amendments of the company charter:None 4.Important resolutions III.Business report and financial statements: Ratification of 2023 Business Report and Financial Statements 5.Important resolutions IV.Election for directors and supervisors:None 6.Important resolutions V.Other matters:None 7.Any other matters that need to be specified:None |
|
2024/05/02 | 17:06:28 | Medeon Board of Directors resolved not to proceed the private placement of common shares approved by the 2023 Annual Shareholders’ Meeting. | |
SEQ_NO |
2 |
Date of announcement |
2024/05/02 |
Time of announcement |
17:06:28 |
Subject |
Medeon Board of Directors resolved not to proceed the private placement of common shares approved by the 2023 Annual Shareholders' Meeting. |
Date of events |
2024/05/02
|
To which item it meets |
paragraph 16 |
Statement |
1.Date of the board of directors resolution for the change:2024/05/02 2.Effective registration date of the original plan:NA 3.Resolution date of additional issuance:NA 4.Major change Reason for the change: The Company resolved on June 19, 2023 to proceed with the issuing no more than 35,000,000 common shares for capital increase through private placement by the Shareholders’Meeting. The issuing shall be completed within 1 year from the date of the resolution of the Shareholders’ Meeting, with the maximum number of installments not exceeding three. Due to the period of the private placement proposal is going to expire and the qualified strategic investors have not yet been identified, the Medeon board meeting dated May 2, 2024 has resolved not to proceed the private placement of common shares for rest of the period. 5.Content of each and every successive previously changed plan for raising of funds before and after change:NA 6.Projected timetable for execution:NA 7.Projected completion date:NA 8.Projected possible benefits:NA 9.Difference from original projected benefits:NA 10.Effect of the current change on shareholder equity:NA 11.Abstract of the original lead underwriter’s appraisal opinion:NA 12.Any other matters that need to be specified:None |
|
2024/05/02 | 17:00:38 | Medeon Board of Directors approved the 2024Q1 consolidated financial reports | |
SEQ_NO |
1 |
Date of announcement |
2024/05/02 |
Time of announcement |
17:00:38 |
Subject |
Medeon Board of Directors approved the 2024Q1 consolidated financial reports |
Date of events |
2024/05/02
|
To which item it meets |
paragraph 31 |
Statement |
1.Date of the board of directors submitted or approved:2024/05/02 2.Date of the audit committee approved:2024/05/02 3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX): 2024/01/01~2024/03/31 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):47,141 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):4,154 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):(227,124) 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):(214,799) 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):(214,513) 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):(199,827) 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):(2.17) 11.Total assets end of the period (thousand NTD):2,557,756 12.Total liabilities end of the period (thousand NTD):379,695 13.Equity attributable to owners of parent end of the period (thousand NTD):2,133,549 14.Any other matters that need to be specified:None |
|
2024/04/24 | 16:33:45 | Announcement for the Board of Directors meeting date to approve the first-quarter 2024 financial report | |
SEQ_NO |
1 |
Date of announcement |
2024/04/24 |
Time of announcement |
16:33:45 |
Subject |
Announcement for the Board of Directors meeting date to approve the first-quarter 2024 financial report |
Date of events |
2024/04/24
|
To which item it meets |
paragraph 31 |
Statement |
1.Date of a notice of the board of directors meeting is issued:2024/04/24 2.Expected date of the board of directors meeting is convened:2024/05/02 3.Expected year and quarter of the financial reports or the annual self-assessed financial information submitted to the board of directors or approved by the board of directors:First-Quarter 2024 4.Any other matters that need to be specified:None |
|
2024/02/29 | 17:06:57 | BOD of Medeon’s major subsidiary Prodeon Medical Corporation resolved to convene the 2024 Annual Shareholders’ meeting | |
SEQ_NO |
6 |
Date of announcement |
2024/02/29 |
Time of announcement |
17:06:57 |
Subject |
BOD of Medeon’s major subsidiary Prodeon Medical Corporation resolved to convene the 2024 Annual Shareholders’ meeting |
Date of events |
2024/02/29
|
To which item it meets |
paragraph 17 |
Statement |
1.Date of the board of directors resolution:2024/02/29 2.General shareholders’ meeting date:2024/05/24 3.General shareholders’ meeting location: No. 116, Hougang St., Shilin Dist., Taipei City, Taiwan (R.O.C.) 4.Cause for convening the meeting I.Reported matters: (1) 2023 Business Report (2) 2023 Supervisor’s Review Report 5.Cause for convening the meeting II.Acknowledged matters: (1) 2023 Business Report and Financial Statements (2) 2023 deficit offset proposal 6.Cause for convening the meeting III, Matters for Discussion:NA 7.Cause for convening the meeting IV.Election matters:NA 8.Cause for convening the meeting V.Other Proposals:NA 9.Cause for convening the meeting VI.Extemporary Motions:NA 10.Book closure starting date:2024/04/25 11.Book closure ending date:2024/05/24 12.Any other matters that need to be specified:NA |
|
2024/02/29 | 17:01:20 | BOD of Medeon’s major subsidiary Prodeon Medical Corporation resolved not to distribute dividends | |
SEQ_NO |
5 |
Date of announcement |
2024/02/29 |
Time of announcement |
17:01:20 |
Subject |
BOD of Medeon’s major subsidiary Prodeon Medical Corporation resolved not to distribute dividends |
Date of events |
2024/02/29
|
To which item it meets |
paragraph 14 |
Statement |
1.Date of the board of directors resolution:2024/02/29 2.Type and monetary amount of dividend distribution:not to distribute 3.Any other matters that need to be specified:None |
|
2024/02/29 | 16:59:40 | Medeon Board of Directors resolved the convening of the 2024 Annual Shareholders’ Meeting | |
SEQ_NO |
4 |
Date of announcement |
2024/02/29 |
Time of announcement |
16:59:40 |
Subject |
Medeon Board of Directors resolved the convening of the 2024 Annual Shareholders' Meeting |
Date of events |
2024/02/29
|
To which item it meets |
paragraph 17 |
Statement |
1.Date of the board of directors resolution:2024/02/29 2.General shareholders’ meeting date:2024/06/12 3.General shareholders’ meeting location: 11F., No. 97, Sec. 2, Dunhua S. Rd., Taipei City, Taiwan (R.O.C.) (MasterLink Securities Conference Room) 4.Shareholders meeting will be held by means of (physical shareholders meeting/ visual communication assisted shareholders meeting / visual communication shareholders meeting):Physical shareholders meeting 5.Cause for convening the meeting I.Reported matters: (1) To Report the Company’s 2023 Business Report (2) To Report Audit Committee’s Review Report on the 2023 Financial Statements (3) To Report the Implementation Status of the Private Placement (4) To Report the Directors’ Remuneration for the year 2023 6.Cause for convening the meeting II.Acknowledged matters: (1) To ratify the Company’s 2023 Business Report and Financial Statements (2) To Ratify the Company’s 2023 deficit offset proposal 7.Cause for convening the meeting III.Matters for Discussion: (1) Proposal of the private placement by issuing common shares 8.Cause for convening the meeting IV.Election matters: (1) To elect the 6th session of Directors 9.Cause for convening the meeting V.Other Proposals: (1) To release newly elected directors or its representatives from Non-Competition Restrictions 10.Cause for convening the meeting VI.Extemporary Motions:None 11.Book closure starting date:2024/04/14 12.Book closure ending date:2024/06/12 13.Any other matters that need to be specified:None |
|
2024/02/29 | 16:57:28 | Medeon Board of Directors resolved the plan for dividend distribution | |
SEQ_NO |
3 |
Date of announcement |
2024/02/29 |
Time of announcement |
16:57:28 |
Subject |
Medeon Board of Directors resolved the plan for dividend distribution |
Date of events |
2024/02/29
|
To which item it meets |
paragraph 14 |
Statement |
1.Date of the board of directors resolution:2024/02/29 2.Year or quarter which dividends belong to :2023 3.Period which dividends belong to:2023/01/01~2023/12/31 4.Appropriations of earnings in cash dividends to shareholders (NT$ per share):0 5.Cash dividends distributed from legal reserve and capital reserve to shareholders (NT$ per share):0 6.Total amount of cash dividends to shareholders (NT$):0 7.Appropriations of earnings in stock dividends to shareholders (NT$ per share):0 8.Stock dividends distributed from legal reserve and capital reserve to shareholders (NT$ per share):0 9.Total amount of stock dividends to shareholders (shares):0 10.Any other matters that need to be specified:None 11.Per value of common stock:NT$10 |
|
2024/02/29 | 16:56:17 | Medeon Board of Directors resolved the proposal of private placement to issue additional common shares | |
SEQ_NO |
2 |
Date of announcement |
2024/02/29 |
Time of announcement |
16:56:17 |
Subject |
Medeon Board of Directors resolved the proposal of private placement to issue additional common shares |
Date of events |
2024/02/29
|
To which item it meets |
paragraph 11 |
Statement |
1.Date of the board of directors resolution:2024/02/29 2.Types of securities privately placed:The Company’s common shares 3.Counterparties for private placement and their relationship with the Company: According to Article 43-6 of the Securities and Exchange Act, the Financial Supervisory Commission’s Order No. SFB 11220383220 issued on September 12,2023, and the Directions for Public Companies Conducting Private Placement of Securities, only the following parties are qualified as specific investors of the private placement: A.Insiders of the Company The reason is that insiders know the operation of the Company very well and can directly or indirectly contribute to the operation of the Company. Therefore, placees in this instance of private placement include the insiders. The list of these insiders is shown below: a.The list of these insiders and the relation with the Company: (1) Medeon, Inc. (USA)/ Institutional Director of the Company (2) Center Laboratories, Inc./ Institutional Director of the Company (3) Yue-Teh Jang/ Representative of Medeon, Inc. of the USA, an Institutional Director of the Company. Chairman and President of the Company (4) Jung-Chin Lin/ Representative of Center Laboratories, Inc., an Institutional Director of the Company (5) Chih-Hsiung Wu/ Representative of Center Laboratories, Inc., an Institutional Director of the Company (6) Hong-Jen Chang/Director of the Company (7) Hsin-Yuan Fang /Director of the Company (8) Chi-Hang Yang/ Independent Director of the Company (9) Chia-Ying Ma/ Independent Director of the Company (10) Jerome Shen/ Independent Director of the Company (11) Jien-Wei Yeh/ Independent Director of the Company (12) Albert Weng/ Manager of the Company (13) Greta Chang/ Manager of the Company (14) Jenny Chen/ Manager of the Company (15) Pei Chen/ Manager of the Company (16) Janice Chang/ Manager of the Company (17) Tori Lin/ Accounting Officer of the Company b.Institutional investors’ Names of the top 10 shareholders and proportion of shareholding and the relation with the Company: (1) Medeon, Inc. (USA) Yue-Teh Jang (100%)/ The Chairman of this company is the Chairman and President of the Company. (2) Center Laboratories, Inc. Li Rong Technology Co., Ltd. (8.70%)/ The Chairman of this company is the spouse of the representative of an Institutional Director of the Company. Royal Food Co., Ltd. (5.99%)/ The Chairman of this company is a representative of an Institutional Director of the Company. Jason Technology Co., Ltd. (2.37%)/ The Chairman of this company is the spouse of the representative of an Institutional Director of the Company. Farglory Life Insurance Inc. (1.63%)/ None You De Investment Consulting Co., Ltd. (1.38%)/ The Chairman of this company is also the Chairperson of an Institutional Director of theCompany. MasterLink Securities Corp. (1.07%)/ None Mumozi Inc. (1.03%)/ None Yong Lian Co., Ltd. (1.00%)/ None Wechen Co. Ltd. (0.89%)/ None JPMorgan Chase Bank N.A. Taipei Branch in Custody for Vanguard TotalInternational Stock Index Fund, a series of Vanguard Star Funds (0.86%)/ None Placees should be strategic investors: It is necessary to bring in strategic investors that could contribute to the development of the Company in the future, improvement of financial structure, and upgrade the profitability of the Company. It is expected that with the assistance of their capital, technology and knowledge, the Company will be able to grow steadily in the future. 4.Number of shares or bonds privately placed: Within the limit of 35,000,000 shares 5.Amount limit of the private placement: Within the limit of 35,000,000 shares of common stock, the private placement will be conducted in installments within one year from the date of the shareholders’ meeting, with the maximum number of installments not exceeding three. 6.Pricing basis of private placement and its reasonableness: The reference price for the private placement is set at the higher of the following two benchmark prices: A.The average of the closing prices of common shares for one or three or five (alternative) business days prior to the pricing date, excluding the ex-rights and dividends of the nil-paid allotment of shares and after adding back the capital reduction and ex-rights. B.The average of the closing prices of the common shares for the 30 business days preceding the pricing date, excluding the ex-rights and dividends of the nil-paid allotment, and after adding back the capital reduction and ex-rights. The price of common shares issued in the private placement shall be set at a level not less than 80% of the reference price. The actual issuance price of the private placement is proposed to the shareholders’ meeting to authorize the board of directors to determine the price within a range not lower than the percentage resolved at the shareholders’ meeting, taking into account the prevailing market conditions on the pricing date. 7.Use of the funds raised in the private placement: The purpose of each tranche is to increase working capital, accelerate product development, invest in subsidiaries and the medical industry, and develop the Group’s strategic objectives. 8.Reasons for conducting non-public offering: Considering the timing, convenience and cost of issuance, private placement of securities can be accomplished quickly and easily. In addition, securities invested through private placement cannot be transferred in a period of 3 years after issuing. This helps to assure the long-term stable relation between the investors and the Company. As such, offering securities through private placement is adopted. 9.Objections or qualified opinions from independent Board of Directors: None 10.Actual price determination date:NA 11.Reference price:NA 12.Actual private placement price, and conversion or subscription price:NA 13.Rights and obligations of these new shares privately placed: In principle, the rights and obligations of the common shares in the private placement are the same as those of the Company’s existing common shares; however, in accordance with the Securities and Exchange Act, the common shares in the private placement may not be sold within three years from the date of delivery, except to the parties to whom they are transferred in accordance with Article 43-8 of the Securities and Exchange Act. After three years from the date of delivery, the Company intends to request the shareholders’ meeting to authorize the Board of Directors to apply to the relevant authorities for a public offering and listing of the Company’s common shares in accordance with the relevant regulations. 14.Reference date for any additional share exchange, stock swap, or subscription:NA 15.Possible dilution of equity in case of any additional share exchange, stock swap, or subscription:NA 16.For additional share exchange or subscription, possible influence of change in shareholding ratio of TPEx -listed common shares if all privately placed corporate bonds are converted and shares subscribed for (no.of TPEx -listed common shares (a), (a) / outstanding common shares):NA 17.Please explain any countermeasures for lower circulation in shareholding if the aforesaid estimated no.of TPEx -listed common shares does not reach 5 million and the ratio does not reach 25%:NA 18.Any other matters that need to be specified: (1)The main contents of the private placement plan, including the actual issue price, the number of shares to be issued, the terms of the issue, the pricing date, the base date of the capital increase, the planned projects, the amount to be raised, the estimated progress, the estimated benefits to be generated, and all other matters related to the issue plan, in addition to the pricing percentage of the private placement. The above and in the future, in the event of changes in laws and regulations, amendments as directed by the competent authorities, or amendments based on operational evaluations or in response to objective market conditions, the shareholders’ meeting will also be requested to authorize the Board of Directors to handle such matters at its sole discretion. (2)In connection with the private placement of securities, it is proposed that the shareholders’ meeting authorize the chairman of the board of directors or his or her designee to sign and negotiate on behalf of the Company all contracts and documents relating to the private placement and to conduct all matters necessary for the Company in connection with the private placement. |
|
2024/02/29 | 16:55:05 | Medeon Board of Directors approved the 2023 consolidated financial reports | |
SEQ_NO |
1 |
Date of announcement |
2024/02/29 |
Time of announcement |
16:55:05 |
Subject |
Medeon Board of Directors approved the 2023 consolidated financial reports |
Date of events |
2024/02/29
|
To which item it meets |
paragraph 31 |
Statement |
1.Date of the board of directors submitted or approved:2024/02/29 2.Date of the audit committee approved:2024/02/29 3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX): 2023/01/01~2023/12/31 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):196,263 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):14,377 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):(839,567) 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):(1,230,688) 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):(1,269,973) 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):(1,204,615) 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):(13.09) 11.Total assets end of the period (thousand NTD):2,747,146 12.Total liabilities end of the period (thousand NTD):375,651 13.Equity attributable to owners of parent end of the period (thousand NTD):2,371,495 14.Any other matters that need to be specified:None |
|